Restoring blood-clotting ability: mouse study shows novel engineered coagulation factor could have promise for tackling anticoagulant side effects
In a novel study from the Children’s Hospital of Philadelphia and the University of Pennsylvania (both Philadelphia, PA, USA), a variant of coagulation factor Xa was able to reverse the anticoagulation effects of blood-thinning drugs in animal models and could be used for reversing the effects of FXa inhibitors.
Please sign in or register for FREE
Sign in to MedChemNet
Register to MedChemNet – the medicinal chemistry network
MedChemNet is a communal space where industry and academic professionals can come together to discuss the latest research and developments, share thoughts and opinions, and build valuable international relationships.